Technical Analysis for GNMK - GenMark Diagnostics, Inc.

Grade Last Price % Change Price Change
grade B 6.01 1.01% 0.06
GNMK closed up 1.01 percent on Friday, January 18, 2019, on 55 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical GNMK trend table...

Date Alert Name Type % Chg
Jan 18 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup 1.01%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.01%
Jan 17 Narrow Range Bar Range Contraction 1.01%
Jan 17 NR7 Range Contraction 1.01%
Jan 17 Inside Day Range Contraction 1.01%
Jan 17 Wide Bands Range Expansion 1.01%

Older signals for GNMK ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company's products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual's ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual's increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company's diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company engages in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.
Is GNMK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.81
52 Week Low 3.58
Average Volume 448,394
200-Day Moving Average 6.3642
50-Day Moving Average 4.989
20-Day Moving Average 5.2475
10-Day Moving Average 5.983
Average True Range 0.3356
ADX 31.54
+DI 32.4875
-DI 17.1623
Chandelier Exit (Long, 3 ATRs ) 5.6332
Chandelier Exit (Short, 3 ATRs ) 4.5868
Upper Bollinger Band 6.9312
Lower Bollinger Band 3.5638
Percent B (%b) 0.73
BandWidth 64.17151
MACD Line 0.3564
MACD Signal Line 0.2732
MACD Histogram 0.0832
Fundamentals Value
Market Cap 328.55 Million
Num Shares 54.7 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -4.93
Price-to-Sales 8.35
Price-to-Book 4.53
PEG Ratio 0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.31
Resistance 3 (R3) 6.29 6.17 6.26
Resistance 2 (R2) 6.17 6.09 6.18 6.24
Resistance 1 (R1) 6.09 6.05 6.13 6.11 6.23
Pivot Point 5.97 5.97 5.99 5.98 5.97
Support 1 (S1) 5.89 5.89 5.93 5.91 5.79
Support 2 (S2) 5.77 5.85 5.78 5.78
Support 3 (S3) 5.69 5.77 5.76
Support 4 (S4) 5.71